Physician profile
Nicholas Berry
NPI 1639816382
$1,704.14
in general payments reported to CMS, 2019-2025
12 companies · $855 in 2025
The $855 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $150 · 2024: $699 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,604 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.15 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $463.98 | 2023-2025 | Libtayo, Dupixent |
| Sun Pharmaceutical Industries INC. | $313.48 | 2025 | |
| Genzyme Corporation | $230.34 | 2024 | |
| Abbvie INC. | $162.03 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.58 | 2024 | Spevigo |
| Incyte Corporation | $146.00 | 2024 | Opzelura |
| Janssen Biotech, INC. | $99.99 | 2024 | Tremfya |
| Ani Pharmaceuticals, INC. | $34.90 | 2025 | Purified Cortrophin Gel, Veregen |
| Lilly USA, LLC | $33.98 | 2024 | Ebglyss, Taltz, Olumiant |
| Journey Medical Corporation | $28.60 | 2023 | |
| Arcutis Biotherapeutics, INC. | $20.63 | 2025 | Zoryve |
| Dermavant Sciences, INC. | $19.63 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.